5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Cerebrovascular O
events O
, O
including O
stroke O
, O
in O
elderly O
patients O
with O
dementia-related O
psychosis O
: O
RISPERDAL O
( O
r O
) O
is O
not O
approved O
for O
use O
in O
patients O
with O
dementia-related O
psychosis O
. O

( O
5.2 O
) O
* O
Neuroleptic O
Malignant O
Syndrome O
: O
Manage O
with O
immediate O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
and O
close O
monitoring O
. O

( O
5.3 O
) O
* O
Tardive O
dyskinesia O
: O
Consider O
discontinuing O
RISPERDAL O
( O
r O
) O
if O
clinically O
indicated O
. O

( O
5.4 O
) O
* O
* O
Hyperglycemia O
and O
Diabetes O
Mellitus O
: O
Monitor O
patients O
for O
symptoms O
of O
hyperglycemia O
including O
polydipsia O
, O
polyuria O
, O
polyphagia O
, O
and O
weakness O
. O

Monitor O
glucose O
regularly O
in O
patients O
with O
diabetes O
or O
at O
risk O
for O
diabetes O
. O

( O
5.5 O
) O
* O
Dyslipidemia O
: O
Undesirable O
alterations O
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

( O
5.5 O
) O
* O
Weight O
Gain O
: O
Significant O
weight O
gain O
has O
been O
reported O
. O

Monitor O
weight O
gain O
. O

( O
5.5 O
) O
Metabolic O
Changes O
: O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic O
changes O
that O
may O
increase O
cardiovascular/ O
cerebrovascular O
risk O
. O

These O
metabolic O
changes O
include O
hyperglycemia O
, O
dyslipidemia O
, O
and O
weight O
gain O
. O

( O
5.5 O
) O
* O
Hyperprolactinemia O
: O
Prolactin O
elevations O
occur O
and O
persist O
during O
chronic O
administration O
. O

( O
5.6 O
) O
* O
Orthostatic O
hypotension O
: O
For O
patients O
at O
risk O
, O
consider O
a O
lower O
starting O
dose O
and O
slower O
titration O
. O

( O
5.7 O
) O
* O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
: O
Perform O
complete O
blood O
counts O
in O
patients O
with O
a O
history O
of O
clinically O
significant O
low O
white O
blood O
cell O
count O
( O
WBC O
) O
. O

Consider O
discontinuing O
RISPERDAL O
( O
r O
) O
if O
a O
clinically O
significant O
decline O
in O
WBC O
occurs O
in O
the O
absence O
of O
other O
causative O
factors O
. O

( O
5.9 O
) O
* O
Potential O
for O
cognitive O
and O
motor O
impairment O
: O
Use O
caution O
when O
operating O
machinery O
. O

( O
5.10 O
) O
* O
Seizures O
: O
Use O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures O
or O
with O
conditions O
that O
lower O
the O
seizure O
threshold O
. O

( O
5.11 O
) O
5.1 O
Increased O
Mortality O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
treated O
with O
antipsychotic O
drugs O
are O
at O
an O
increased O
risk O
of O
death B-NonOSE_AE
. O

Analyses O
of O
17 O
placebo-controlled O
trials O
( O
modal O
duration O
of O
10 O
weeks O
) O
, O
largely O
in O
patients O
taking O
atypical O
antipsychotic O
drugs O
, O
revealed O
a O
risk O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
of O
between O
1.6 O
to O
1.7 O
times O
the O
risk O
of O
death B-NonOSE_AE
in O
placebo-treated O
patients O
. O

Over O
the O
course O
of O
a O
typical O
10-week O
controlled O
trial O
, O
the O
rate O
of O
death B-NonOSE_AE
in O
drug-treated O
patients O
was O
about O
4.5 O
% O
, O
compared O
to O
a O
rate O
of O
about O
2.6 O
% O
in O
the O
placebo O
group O
. O

Although O
the O
causes O
of O
death B-NonOSE_AE
were O
varied O
, O
most O
of O
the O
deaths B-NonOSE_AE
appeared O
to O
be O
either O
cardiovascular I-NonOSE_AE
( O
e.g. O
, O
heart B-NonOSE_AE
failure I-NonOSE_AE
, O
sudden B-NonOSE_AE
death I-NonOSE_AE
) O
or O
infectious B-NonOSE_AE
( O
e.g. O
, O
pneumonia B-NonOSE_AE
) O
in O
nature O
. O

Observational O
studies O
suggest O
that O
, O
similar O
to O
atypical O
antipsychotic O
drugs O
, O
treatment O
with O
conventional O
antipsychotic O
drugs O
may O
increase O
mortality B-NonOSE_AE
. O

The O
extent O
to O
which O
the O
findings O
of O
increased O
mortality O
in O
observational O
studies O
may O
be O
attributed O
to O
the O
antipsychotic O
drug O
as O
opposed O
to O
some O
characteristic O
( O
s O
) O
of O
the O
patients O
is O
not O
clear O
. O

In O
two O
of O
four O
placebo-controlled O
trials O
in O
elderly B-Not_AE_Candidate
patients O
with O
dementia I-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
, O
a O
higher O
incidence O
of O
mortality O
was O
observed O
in O
patients O
treated O
with O
furosemide O
plus O
RISPERDAL O
( O
r O
) O
when O
compared O
to O
patients O
treated O
with O
RISPERDAL O
( O
r O
) O
alone O
or O
with O
placebo O
plus O
furosemide O
. O

No O
pathological O
mechanism O
has O
been O
identified O
to O
explain O
this O
finding O
, O
and O
no O
consistent O
pattern O
for O
cause O
of O
death B-NonOSE_AE
was O
observed O
. O

RISPERDAL O
( O
r O
) O
( O
risperidone O
) O
is O
not O
approved O
for O
the O
treatment O
of O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
[ O
see O
Boxed O
Warning O
] O
. O

5.2 O
Cerebrovascular O
Adverse O
Reactions O
, O
Including O
Stroke O
, O
in O
Elderly O
Patients O
with O
Dementia-Related O
Psychosis O
Cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
reactions I-NonOSE_AE
( O
e.g. O
, O
stroke B-NonOSE_AE
, O
transient B-NonOSE_AE
ischemic I-NonOSE_AE
attack I-NonOSE_AE
) O
, O
including O
fatalities B-NonOSE_AE
, O
were O
reported O
in O
patients O
( O
mean O
age O
85 O
years O
; O
range O
73-97 O
) O
in O
trials O
of O
risperidone O
in O
elderly O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
. O

In O
placebo-controlled O
trials O
, O
there O
was O
a O
significantly O
higher O
incidence O
of O
cerebrovascular B-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
in O
patients O
treated O
with O
risperidone O
compared O
to O
patients O
treated O
with O
placebo O
. O

RISPERDAL O
( O
r O
) O
is O
not O
approved O
for O
the O
treatment O
of O
patients O
with O
dementia B-Not_AE_Candidate
- I-Not_AE_Candidate
related I-Not_AE_Candidate
psychosis I-Not_AE_Candidate
. O

[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
5.3 O
Neuroleptic O
Malignant O
Syndrome O
Antipsychotic O
drugs O
including O
RISPERDAL O
( O
r O
) O
can O
cause O
a O
potentially O
fatal B-NonOSE_AE
symptom O
complex O
referred O
to O
as O
Neuroleptic B-OSE_Labeled_AE
Malignant I-OSE_Labeled_AE
Syndrome I-OSE_Labeled_AE
( I-OSE_Labeled_AE
NMS I-OSE_Labeled_AE
) O
. O

Clinical O
manifestations O
of O
NMS B-NonOSE_AE
include O
hyperpyrexia B-NonOSE_AE
, O
muscle B-NonOSE_AE
rigidity I-NonOSE_AE
, O
altered B-NonOSE_AE
mental I-NonOSE_AE
status I-NonOSE_AE
, O
and O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
irregular B-NonOSE_AE
pulse I-NonOSE_AE
or O
blood O
pressure O
, O
tachycardia B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
and O
cardiac B-NonOSE_AE
dysrhythmia I-NonOSE_AE
) O
. O

Additional O
signs O
may O
include O
elevated B-NonOSE_AE
creatine I-NonOSE_AE
phosphokinase I-NonOSE_AE
( I-NonOSE_AE
CPK I-NonOSE_AE
) O
, O
myoglobinuria B-NonOSE_AE
, O
rhabdomyolysis B-NonOSE_AE
, O
and O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
. O

The O
diagnostic O
evaluation O
of O
patients O
with O
this O
syndrome O
is O
complicated O
. O

In O
arriving O
at O
a O
diagnosis O
, O
it O
is O
important O
to O
identify O
cases O
in O
which O
the O
clinical O
presentation O
includes O
both O
serious O
medical O
illness O
( O
e.g. O
, O
pneumonia B-NonOSE_AE
, O
systemic B-NonOSE_AE
infection I-NonOSE_AE
, O
etc O
. O
) O

and O
untreated O
or O
inadequately O
treated O
extrapyramidal B-NonOSE_AE
signs I-NonOSE_AE
and I-NonOSE_AE
symptoms I-NonOSE_AE
( I-NonOSE_AE
EPS I-NonOSE_AE
) O
. O

Other O
important O
considerations O
in O
the O
differential O
diagnosis O
include O
central B-NonOSE_AE
anticholinergic I-NonOSE_AE
toxicity I-NonOSE_AE
, O
heat B-NonOSE_AE
stroke I-NonOSE_AE
, O
drug B-NonOSE_AE
fever I-NonOSE_AE
, O
and O
primary B-NonOSE_AE
central I-NonOSE_AE
nervous I-NonOSE_AE
system I-NonOSE_AE
pathology I-NonOSE_AE
. O

The O
management O
of O
NMS B-NonOSE_AE
should O
include O
: O
( O
1 O
) O
immediate O
discontinuation O
of O
antipsychotic O
drugs O
and O
other O
drugs O
not O
essential O
to O
concurrent O
therapy O
; O
( O
2 O
) O
intensive O
symptomatic O
treatment O
and O
medical O
monitoring O
; O
and O
( O
3 O
) O
treatment O
of O
any O
concomitant O
serious O
medical O
problems O
for O
which O
specific O
treatments O
are O
available O
. O

There O
is O
no O
general O
agreement O
about O
specific O
pharmacological O
treatment O
regimens O
for O
uncomplicated O
NMS B-NonOSE_AE
. O

If O
a O
patient O
requires O
antipsychotic O
drug O
treatment O
after O
recovery O
from O
NMS B-NonOSE_AE
, O
the O
potential O
reintroduction O
of O
drug O
therapy O
should O
be O
carefully O
considered O
. O

The O
patient O
should O
be O
carefully O
monitored O
, O
since O
recurrences O
of O
NMS B-NonOSE_AE
have O
been O
reported O
. O

5.4 O
Tardive B-OSE_Labeled_AE
Dyskinesia I-OSE_Labeled_AE
A O
syndrome O
of O
potentially O
irreversible O
, O
involuntary O
, O
dyskinetic B-OSE_Labeled_AE
movements I-OSE_Labeled_AE
may O
develop O
in O
patients O
treated O
with O
antipsychotic O
drugs O
. O

The O
risk O
of O
developing O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
and O
the O
likelihood O
that O
it O
will O
become O
irreversible O
are O
believed O
to O
increase O
as O
the O
duration O
of O
treatment O
and O
the O
total O
cumulative O
dose O
of O
antipsychotic O
drugs O
administered O
to O
the O
patient O
increase O
. O

However O
, O
the O
syndrome O
can O
develop O
, O
although O
much O
less O
commonly O
, O
after O
relatively O
brief O
treatment O
periods O
at O
low O
doses O
. O

There O
is O
no O
known O
treatment O
for O
established O
cases O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
, O
although O
the O
syndrome O
may O
remit O
, O
partially O
or O
completely O
, O
if O
antipsychotic O
treatment O
is O
withdrawn O
. O

Antipsychotic O
treatment O
, O
itself O
, O
however O
, O
may O
suppress O
( O
or O
partially O
suppress O
) O
the O
signs O
and O
symptoms O
of O
the O
syndrome O
and O
thereby O
may O
possibly O
mask O
the O
underlying O
process O
. O

The O
effect O
that O
symptomatic O
suppression O
has O
upon O
the O
long-term O
course O
of O
the O
syndrome O
is O
unknown O
. O

Given O
these O
considerations O
, O
prescribe O
RISPERDAL O
( O
r O
) O
in O
a O
manner O
that O
is O
most O
likely O
to O
minimize O
the O
occurrence O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
. O

Chronic O
antipsychotic O
treatment O
should O
generally O
be O
reserved O
for O
patients O
who O
suffer O
from O
a O
chronic O
illness O
that O
: O
( O
1 O
) O
is O
known O
to O
respond O
to O
antipsychotic O
drugs O
, O
and O
( O
2 O
) O
for O
whom O
alternative O
, O
equally O
effective O
, O
but O
potentially O
less O
harmful O
treatments O
are O
not O
available O
or O
appropriate O
. O

In O
patients O
who O
do O
require O
chronic O
treatment O
, O
the O
smallest O
dose O
and O
the O
shortest O
duration O
of O
treatment O
producing O
a O
satisfactory O
clinical O
response O
should O
be O
sought O
. O

The O
need O
for O
continued O
treatment O
should O
be O
reassessed O
periodically O
. O

If O
signs O
and O
symptoms O
of O
tardive B-NonOSE_AE
dyskinesia I-NonOSE_AE
appear O
in O
a O
patient O
treated O
with O
RISPERDAL O
( O
r O
) O
, O
consider O
drug O
discontinuation O
. O

However O
, O
some O
patients O
may O
require O
treatment O
with O
RISPERDAL O
( O
r O
) O
despite O
the O
presence O
of O
the O
syndrome O
. O

5.5 O
Metabolic O
Changes O
Atypical O
antipsychotic O
drugs O
have O
been O
associated O
with O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
that O
may O
increase O
cardiovascular/cerebrovascular O
risk O
. O

These O
metabolic B-NonOSE_AE
changes I-NonOSE_AE
include O
hyperglycemia B-OSE_Labeled_AE
, O
dyslipidemia B-OSE_Labeled_AE
, O
and O
body B-OSE_Labeled_AE
weight I-OSE_Labeled_AE
gain I-OSE_Labeled_AE
. O

While O
all O
of O
the O
drugs O
in O
the O
class O
have O
been O
shown O
to O
produce O
some O
metabolic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
each O
drug O
has O
its O
own O
specific O
risk O
profile O
. O

Hyperglycemia O
and O
Diabetes O
Mellitus O
Hyperglycemia B-OSE_Labeled_AE
and O
diabetes B-OSE_Labeled_AE
mellitus I-OSE_Labeled_AE
, O
in O
some O
cases O
extreme O
and O
associated O
with O
ketoacidosis B-OSE_Labeled_AE
or O
hyperosmolar B-OSE_Labeled_AE
coma I-OSE_Labeled_AE
or O
death B-NonOSE_AE
, O
have O
been O
reported O
in O
patients O
treated O
with O
atypical O
antipsychotics O
including O
RISPERDAL O
( O
r O
) O
. O

Assessment O
of O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
glucose B-NonOSE_AE
abnormalities I-NonOSE_AE
is O
complicated O
by O
the O
possibility O
of O
an O
increased O
background O
risk O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
patients O
with O
schizophrenia B-Not_AE_Candidate
and O
the O
increasing O
incidence O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
in O
the O
general O
population O
. O

Given O
these O
confounders O
, O
the O
relationship O
between O
atypical O
antipsychotic O
use O
and O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
is O
not O
completely O
understood O
. O

However O
, O
epidemiological O
studies O
suggest O
an O
increased O
risk O
of O
treatment-emergent O
hyperglycemia B-OSE_Labeled_AE
- I-OSE_Labeled_AE
related I-OSE_Labeled_AE
adverse I-OSE_Labeled_AE
events I-OSE_Labeled_AE
in O
patients O
treated O
with O
the O
atypical O
antipsychotics O
. O

Precise O
risk O
estimates O
for O
hyperglycemia B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
adverse I-NonOSE_AE
events I-NonOSE_AE
in O
patients O
treated O
with O
atypical O
antipsychotics O
are O
not O
available O
. O

Patients O
with O
an O
established O
diagnosis O
of O
diabetes B-Not_AE_Candidate
mellitus I-Not_AE_Candidate
who O
are O
started O
on O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
be O
monitored O
regularly O
for O
worsening B-NonOSE_AE
of I-NonOSE_AE
glucose I-NonOSE_AE
control I-NonOSE_AE
. O

Patients O
with O
risk O
factors O
for O
diabetes B-NonOSE_AE
mellitus I-NonOSE_AE
( O
e.g. O
, O
obesity B-Not_AE_Candidate
, O
family B-Not_AE_Candidate
history I-Not_AE_Candidate
of I-Not_AE_Candidate
diabetes I-Not_AE_Candidate
) O
who O
are O
starting O
treatment O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
undergo O
fasting O
blood O
glucose O
testing O
at O
the O
beginning O
of O
treatment O
and O
periodically O
during O
treatment O
. O

Any O
patient O
treated O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
be O
monitored O
for O
symptoms O
of O
hyperglycemia B-NonOSE_AE
including O
polydipsia B-NonOSE_AE
, O
polyuria B-NonOSE_AE
, O
polyphagia B-NonOSE_AE
, O
and O
weakness B-NonOSE_AE
. O

Patients O
who O
develop O
symptoms O
of O
hyperglycemia B-NonOSE_AE
during O
treatment O
with O
atypical O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
should O
undergo O
fasting O
blood O
glucose O
testing O
. O

In O
some O
cases O
, O
hyperglycemia B-NonOSE_AE
has O
resolved O
when O
the O
atypical O
antipsychotic O
, O
including O
RISPERDAL O
( O
r O
) O
, O
was O
discontinued O
; O
however O
, O
some O
patients O
required O
continuation O
of O
anti-diabetic O
treatment O
despite O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
. O

Pooled O
data O
from O
three O
double-blind O
, O
placebo-controlled O
schizophrenia B-Not_AE_Candidate
studies O
and O
four O
double-blind O
, O
placebo-controlled O
bipolar B-Not_AE_Candidate
monotherapy O
studies O
are O
presented O
in O
Table O
2 O
. O

Table O
2 O
. O

Change O
in O
Random O
Glucose O
from O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
with O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
1-8 O
mg/day O
> O
8-16 O
mg/day O
Mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=555 O
n=748 O
n=164 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-1.4 O
0.8 O
0.6 O
Proportion O
of O
patients O
with O
shifts O
Serum B-NonOSE_AE
Glucose I-NonOSE_AE
( I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
to I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
2 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
mg I-NonOSE_AE
/ I-NonOSE_AE
dL I-NonOSE_AE
) O
0.6 O
% O
( O
3/525 O
) O
0.4 O
% O
( O
3/702 O
) O
0 O
% O
( O
0/158 O
) O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+2.8 O
mg/dL O
at O
Week O
24 O
( O
n=151 O
) O
and O
+4.1 O
mg/dL O
at O
Week O
48 O
( O
n=50 O
) O
. O

Data O
from O
the O
placebo-controlled O
3- O
to O
6-week O
study O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
or O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5 O
to O
17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
3 O
. O

Table O
3 O
. O

Change O
in O
Fasting O
Glucose O
from O
Three O
Placebo-Controlled O
, O
3- O
to O
6-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
with O
Schizophrenia O
( O
13-17 O
years O
of O
age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
years O
of O
age O
) O
, O
or O
Autistic O
Disorder O
( O
5 O
to O
17 O
years O
of O
age O
) O
RISPERDAL O
( O
r O
) O
Placebo O
0.5-6 O
mg/day O
Mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
( O
mg/dL O
) O
n=76 O
n=135 O
Serum I-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
-1.3 O
2.6 O
Proportion O
of O
patients O
with O
shifts O
Serum B-OSE_Labeled_AE
Glucose I-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
6 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/64 O
) O
0.8 O
% O
( O
1/120 O
) O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
glucose I-OSE_Labeled_AE
of O
+5.2 O
mg/dL O
at O
Week O
24 O
( O
n=119 O
) O
. O

Dyslipidemia B-OSE_Labeled_AE
Undesirable B-OSE_Labeled_AE
alterations I-OSE_Labeled_AE
in I-OSE_Labeled_AE
lipids I-OSE_Labeled_AE
have O
been O
observed O
in O
patients O
treated O
with O
atypical O
antipsychotics O
. O

Pooled O
data O
from O
7 O
placebo-controlled O
, O
3- O
to O
8- O
week O
, O
fixed- O
or O
flexible-dose O
studies O
in O
adult O
subjects O
with O
schizophrenia B-Not_AE_Candidate
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
are O
presented O
in O
Table O
4 O
. O

Table O
4 O
. O

Change O
in O
Random O
Lipids O
from O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
with O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
1-8 O
mg/day O
> O
8-16 O
mg/day O
Mean O
change O
from O
baseline O
( O
mg/dL O
) O
Cholesterol B-OSE_Labeled_AE
n=559 O
n=742 O
n=156 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
0.6 O
6.9 O
1.8 O
Triglycerides B-OSE_Labeled_AE
n=183 O
n=307 O
n=123 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
-17.4 O
-4.9 O
-8.3 O
Proportion O
of O
patients O
With O
Shifts O
Cholesterol B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
2.7 O
% O
4.3 O
% O
6.3 O
% O
( O
10/368 O
) O
( O
22/516 O
) O
( O
6/96 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.1 O
% O
( O
2/180 O
) O
2.7 O
% O
( O
8/301 O
) O
2.5 O
% O
( O
3/121 O
) O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
) I-OSE_Labeled_AE
non I-OSE_Labeled_AE
- I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
+4.4 O
mg/dL O
at O
Week O
24 O
( O
n=231 O
) O
and O
+5.5 O
mg/dL O
at O
Week O
48 O
( O
n=86 O
) O
; O
and O
( O
b O
) O
non-fasting O
triglycerides O
of O
+19.9 O
mg/dL O
at O
Week O
24 O
( O
n=52 O
) O
. O

Pooled O
data O
from O
3 O
placebo-controlled O
, O
3- O
to O
6-week O
, O
fixed-dose O
studies O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
or O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
5 O
. O

Table O
5 O
. O

Change O
in O
Fasting O
Lipids O
from O
Three O
Placebo-Controlled O
, O
3- O
to O
6-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
with O
Schizophrenia O
( O
13-17 O
Years O
of O
Age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
Years O
of O
Age O
) O
, O
or O
Autistic O
Disorder O
( O
5 O
to O
17 O
Years O
of O
Age O
) O
RISPERDAL O
( O
r O
) O
Placebo O
0.5-6 O
mg/day O
Mean O
change O
from O
baseline O
( O
mg/dL O
) O
Cholesterol B-OSE_Labeled_AE
n=74 O
n=133 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
0.3 O
-0.3 O
LDL B-OSE_Labeled_AE
n=22 O
n=22 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
3.7 O
0.5 O
HDL B-OSE_Labeled_AE
n=22 O
n=22 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
1.6 O
-1.9 O
Triglycerides B-OSE_Labeled_AE
n=77 O
n=138 O
Change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
-9.0 O
-2.6 O
Proportion O
of O
patients O
with O
shifts O
Cholesterol B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
2.4 O
% O
( O
1/42 O
) O
3.8 O
% O
( O
3/80 O
) O
LDL B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
3 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/16 O
) O
0 O
% O
( O
0/16 O
) O
HDL B-OSE_Labeled_AE
( I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
< I-OSE_Labeled_AE
4 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
0 O
% O
( O
0/19 O
) O
10 O
% O
( O
2/20 O
) O
Triglycerides B-OSE_Labeled_AE
( I-OSE_Labeled_AE
< I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
to I-OSE_Labeled_AE
> I-OSE_Labeled_AE
= I-OSE_Labeled_AE
2 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mg I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
dL I-OSE_Labeled_AE
) O
1.5 O
% O
( O
1/65 O
) O
7.1 O
% O
( O
8/113 O
) O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
( I-OSE_Labeled_AE
a I-OSE_Labeled_AE
) I-OSE_Labeled_AE
fasting I-OSE_Labeled_AE
cholesterol I-OSE_Labeled_AE
of O
+2.1 O
mg/dL O
at O
Week O
24 O
( O
n=114 O
) O
; O
( O
b O
) O
fasting O
LDL O
of O
-0.2 O
mg/dL O
at O
Week O
24 O
( O
n=103 O
) O
; O
( O
c O
) O
fasting O
HDL O
of O
+0.4 O
mg/dL O
at O
Week O
24 O
( O
n=103 O
) O
; O
and O
( O
d O
) O
fasting O
triglycerides O
of O
+6.8 O
mg/dL O
at O
Week O
24 O
( O
n=120 O
) O
. O

Weight O
Gain O
Weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
has O
been O
observed O
with O
atypical O
antipsychotic O
use O
. O

Clinical O
monitoring O
of O
weight O
is O
recommended O
. O

Data O
on O
mean O
changes B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
and O
the O
proportion O
of O
subjects O
meeting O
a O
weight B-NonOSE_AE
gain I-NonOSE_AE
criterion O
of O
7 O
% O
or O
greater O
of O
body O
weight O
from O
7 O
placebo-controlled O
, O
3- O
to O
8- O
week O
, O
fixed- O
or O
flexible-dose O
studies O
in O
adult O
subjects O
with O
schizophrenia B-Not_AE_Candidate
or O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
are O
presented O
in O
Table O
6 O
. O

Table O
6 O
. O

Mean O
Change O
in O
Body O
Weight O
( O
kg O
) O
and O
the O
Proportion O
of O
Subjects O
with O
> O
=7 O
% O
Gain O
in O
Body O
Weight O
From O
Seven O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed- O
or O
Flexible-Dose O
Studies O
in O
Adult O
Subjects O
With O
Schizophrenia O
or O
Bipolar O
Mania O
RISPERDAL O
( O
r O
) O
Placebo O
( O
n=597 O
) O
1-8 O
mg/day O
( O
n=769 O
) O
> O
8-16 O
mg/day O
( O
n=158 O
) O
Weight B-OSE_Labeled_AE
( I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Chan I-OSE_Labeled_AE
ge O
f I-OSE_Labeled_AE
rom O
base I-OSE_Labeled_AE
line O
-0.3 O
0.7 O
2.2 O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
increase O
from O
baseline O
2.9 O
% O
8.7 O
% O
20.9 O
% O
In O
longer-term O
, O
controlled O
and O
uncontrolled O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+4.3 O
kg O
at O
Week O
24 O
( O
n=395 O
) O
and O
+5.3 O
kg O
at O
Week O
48 O
( O
n=203 O
) O
. O

Data O
on O
mean B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
and O
the O
proportion O
of O
subjects O
meeting O
the O
criterion O
of O
> O
=7 O
% O
gain B-NonOSE_AE
in I-NonOSE_AE
body I-NonOSE_AE
weight I-NonOSE_AE
from O
nine O
placebo-controlled O
, O
3- O
to O
8-week O
, O
fixed-dose O
studies O
in O
children O
and O
adolescents O
with O
schizophrenia B-Not_AE_Candidate
( O
13-17 O
years O
of O
age O
) O
, O
bipolar B-Not_AE_Candidate
mania I-Not_AE_Candidate
( O
10-17 O
years O
of O
age O
) O
, O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
( O
5-17 O
years O
of O
age O
) O
are O
presented O
in O
Table O
7 O
. O

Table O
7 O
. O

Mean O
Change O
in O
Body O
Weight O
( O
kg O
) O
and O
the O
Proportion O
of O
Subjects O
With O
> O
=7 O
% O
Gain O
in O
Body O
Weight O
From O
Nine O
Placebo-Controlled O
, O
3- O
to O
8-Week O
, O
Fixed-Dose O
Studies O
in O
Children O
and O
Adolescents O
With O
Schizophrenia O
( O
13-17 O
Years O
of O
Age O
) O
, O
Bipolar O
Mania O
( O
10-17 O
Years O
of O
Age O
) O
, O
Autistic O
Disorder O
( O
5 O
to O
17 O
Years O
of O
Age O
) O
or O
Other O
Psychiatric O
Disorders O
( O
5-17 O
Years O
of O
Age O
) O
Placebo O
( O
n=375 O
) O
RISPERDAL O
( O
r O
) O
0.5-6 O
mg/day O
( O
n=448 O
) O
Weight B-OSE_Labeled_AE
( I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
) I-OSE_Labeled_AE
Chan I-OSE_Labeled_AE
ge O
f I-OSE_Labeled_AE
rom O
base I-OSE_Labeled_AE
line O
0.6 O
2.0 O
Weight B-OSE_Labeled_AE
Gain I-OSE_Labeled_AE
> O
=7 O
% O
increase O
from O
baseline O
6.9 O
% O
32.6 O
% O
In O
longer-term O
, O
uncontrolled O
, O
open-label O
extension O
pediatric O
studies O
, O
RISPERDAL O
( O
r O
) O
was O
associated O
with O
a O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
in I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
of O
+5.5 O
kg O
at O
Week O
24 O
( O
n=748 O
) O
and O
+8.0 O
kg O
at O
Week O
48 O
( O
n=242 O
) O
. O

In O
a O
long-term O
, O
open-label O
extension O
study O
in O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
weight B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
was O
reported O
as O
a O
treatment-emergent O
adverse O
event O
in O
14 O
% O
of O
patients O
. O

In O
103 O
adolescent O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
a O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
of I-OSE_Labeled_AE
9 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
was O
observed O
after O
8 O
months O
of O
RISPERDAL O
( O
r O
) O
treatment O
. O

The O
majority O
of O
that O
increase O
was O
observed O
within O
the O
first O
6 O
months O
. O

The O
average O
percentiles O
at O
baseline O
and O
8 O
months O
, O
respectively O
, O
were O
56 O
and O
72 O
for O
weight O
, O
55 O
and O
58 O
for O
height O
, O
and O
51 O
and O
71 O
for O
body O
mass O
index O
. O

In O
long-term O
, O
open-label O
trials O
( O
studies O
in O
patients O
with O
autistic B-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
) O
, O
a O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
of I-OSE_Labeled_AE
7 I-OSE_Labeled_AE
. I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
kg I-OSE_Labeled_AE
after O
12 O
months O
of O
RISPERDAL O
( O
r O
) O
treatment O
was O
observed O
, O
which O
was O
higher O
than O
the O
expected O
normal O
weight B-OSE_Labeled_AE
gain I-OSE_Labeled_AE
( O
approximately O
3 O
to O
3.5 O
kg O
per O
year O
adjusted O
for O
age O
, O
based O
on O
Centers O
for O
Disease O
Control O
and O
Prevention O
normative O
data O
) O
. O

The O
majority O
of O
that O
increase O
occurred O
within O
the O
first O
6 O
months O
of O
exposure O
to O
RISPERDAL O
( O
r O
) O
. O

The O
average O
percentiles O
at O
baseline O
and O
12 O
months O
, O
respectively O
, O
were O
49 O
and O
60 O
for O
weight O
, O
48 O
and O
53 O
for O
height O
, O
and O
50 O
and O
62 O
for O
body O
mass O
index O
. O

In O
one O
3-week O
, O
placebo-controlled O
trial O
in O
children O
and O
adolescent O
patients O
with O
acute B-Not_AE_Candidate
manic I-Not_AE_Candidate
or I-Not_AE_Candidate
mixed I-Not_AE_Candidate
episodes I-Not_AE_Candidate
of I-Not_AE_Candidate
bipolar I-Not_AE_Candidate
I I-Not_AE_Candidate
disorder I-Not_AE_Candidate
, O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
weight I-OSE_Labeled_AE
were O
higher O
in O
the O
RISPERDAL O
( O
r O
) O
groups O
than O
the O
placebo O
group O
, O
but O
not O
dose O
related O
( O
1.90 O
kg O
in O
the O
RISPERDAL O
( O
r O
) O
0.5-2.5 O
mg O
group O
, O
1.44 O
kg O
in O
the O
RISPERDAL O
( O
r O
) O
3-6 O
mg O
group O
, O
and O
0.65 O
kg O
in O
the O
placebo O
group O
) O
. O

A O
similar O
trend O
was O
observed O
in O
the O
mean B-OSE_Labeled_AE
change I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
body I-OSE_Labeled_AE
mass I-OSE_Labeled_AE
index I-OSE_Labeled_AE
. O

When O
treating O
pediatric O
patients O
with O
RISPERDAL O
( O
r O
) O
for O
any O
indication O
, O
weight B-NonOSE_AE
gain I-NonOSE_AE
should O
be O
assessed O
against O
that O
expected O
with O
normal O
growth O
. O

5.6 O
Hyperprolactinemia B-OSE_Labeled_AE
As O
with O
other O
drugs O
that O
antagonize O
dopamine O
D2receptors O
, O
RISPERDAL O
( O
r O
) O
elevates B-OSE_Labeled_AE
prolactin I-OSE_Labeled_AE
levels I-OSE_Labeled_AE
and O
the O
elevation O
persists O
during O
chronic O
administration O
. O

RISPERDAL O
( O
r O
) O
is O
associated O
with O
higher O
levels O
of O
prolactin B-OSE_Labeled_AE
elevation I-OSE_Labeled_AE
than O
other O
antipsychotic O
agents O
. O

Hyperprolactinemia B-NonOSE_AE
may O
suppress B-NonOSE_AE
hypothalamic I-NonOSE_AE
GnRH I-NonOSE_AE
, O
resulting O
in O
reduced B-NonOSE_AE
pituitary I-NonOSE_AE
gonadotropin I-NonOSE_AE
secretion I-NonOSE_AE
. O

This O
, O
in O
turn O
, O
may O
inhibit B-NonOSE_AE
reproductive I-NonOSE_AE
function I-NonOSE_AE
by O
impairing B-NonOSE_AE
gonadal I-NonOSE_AE
steroidogenesis I-NonOSE_AE
in O
both O
female O
and O
male O
patients O
. O

Galactorrhea B-OSE_Labeled_AE
, O
amenorrhea B-OSE_Labeled_AE
, O
gynecomastia B-OSE_Labeled_AE
, O
and O
impotence B-OSE_Labeled_AE
have O
been O
reported O
in O
patients O
receiving O
prolactin-elevating O
compounds O
. O

Long-standing O
hyperprolactinemia B-NonOSE_AE
when O
associated O
with O
hypogonadism B-NonOSE_AE
may O
lead O
to O
decreased B-NonOSE_AE
bone I-NonOSE_AE
density I-NonOSE_AE
in O
both O
female O
and O
male O
subjects O
. O

Tissue O
culture O
experiments O
indicate O
that O
approximately O
one-third O
of O
human O
breast B-NonOSE_AE
cancers I-NonOSE_AE
are O
prolactin O
dependent O
in O
vitro O
, O
a O
factor O
of O
potential O
importance O
if O
the O
prescription O
of O
these O
drugs O
is O
contemplated O
in O
a O
patient O
with O
previously O
detected O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
. O

An O
increase O
in O
pituitary B-NonOSE_AE
gland I-NonOSE_AE
, O
mammary O
gland O
, O
and O
pancreatic O
islet O
cell O
neoplasia I-NonOSE_AE
( O
mammary B-NonOSE_AE
adenocarcinomas I-NonOSE_AE
, O
pituitary B-NonOSE_AE
and O
pancreatic O
adenomas I-NonOSE_AE
) O
was O
observed O
in O
the O
risperidone O
carcinogenicity O
studies O
conducted O
in O
mice O
and O
rats O
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Neither O
clinical O
studies O
nor O
epidemiologic O
studies O
conducted O
to O
date O
have O
shown O
an O
association O
between O
chronic O
administration O
of O
this O
class O
of O
drugs O
and O
tumorigenesis B-NonOSE_AE
in O
humans O
; O
the O
available O
evidence O
is O
considered O
too O
limited O
to O
be O
conclusive O
at O
this O
time O
. O

5.7 O
Orthostatic O
Hypotension O
RISPERDAL O
( O
r O
) O
may O
induce O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
associated O
with O
dizziness B-OSE_Labeled_AE
, O
tachycardia B-OSE_Labeled_AE
, O
and O
in O
some O
patients O
, O
syncope B-OSE_Labeled_AE
, O
especially O
during O
the O
initial O
dose-titration O
period O
, O
probably O
reflecting O
its O
alpha-adrenergic O
antagonistic O
properties O
. O

Syncope B-OSE_Labeled_AE
was O
reported O
in O
0.2 O
% O
( O
6/2607 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
in O
Phase O
2 O
and O
3 O
studies O
in O
adults O
with O
schizophrenia B-Not_AE_Candidate
. O

The O
risk O
of O
orthostatic B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
and O
syncope B-OSE_Labeled_AE
may O
be O
minimized O
by O
limiting O
the O
initial O
dose O
to O
2 O
mg O
total O
( O
either O
once O
daily O
or O
1 O
mg O
twice O
daily O
) O
in O
normal O
adults O
and O
0.5 O
mg O
twice O
daily O
in O
the O
elderly O
and O
patients O
with O
renal B-Not_AE_Candidate
or O
hepatic O
impairment I-Not_AE_Candidate
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
, O
2.4 O
) O
] O
. O

Monitoring O
of O
orthostatic O
vital O
signs O
should O
be O
considered O
in O
patients O
for O
whom O
this O
is O
of O
concern O
. O

A O
dose O
reduction O
should O
be O
considered O
if O
hypotension B-NonOSE_AE
occurs O
. O

RISPERDAL O
( O
r O
) O
should O
be O
used O
with O
particular O
caution O
in O
patients O
with O
known O
cardiovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
( O
history O
of O
myocardial B-Not_AE_Candidate
infarction I-Not_AE_Candidate
or O
ischemia B-Not_AE_Candidate
, O
heart B-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
conduction B-Not_AE_Candidate
abnormalities I-Not_AE_Candidate
) O
, O
cerebrovascular B-Not_AE_Candidate
disease I-Not_AE_Candidate
, O
and O
conditions O
which O
would O
predispose O
patients O
to O
hypotension B-NonOSE_AE
, O
e.g. O
, O
dehydration B-Not_AE_Candidate
and O
hypovolemia B-Not_AE_Candidate
. O

Clinically O
significant O
hypotension B-NonOSE_AE
has O
been O
observed O
with O
concomitant O
use O
of O
RISPERDAL O
( O
r O
) O
and O
antihypertensive B-NonOSE_AE
medication I-NonOSE_AE
. O

5.8 O
Falls O
Somnolence B-OSE_Labeled_AE
, O
postural B-OSE_Labeled_AE
hypotension I-OSE_Labeled_AE
, O
motor B-OSE_Labeled_AE
and O
sensory O
instability I-OSE_Labeled_AE
have O
been O
reported O
with O
the O
use O
of O
antipsychotics O
, O
including O
RISPERDAL O
( O
r O
) O
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
and O
, O
consequently O
, O
fractures B-NonOSE_AE
or O
other O
fall B-NonOSE_AE
- I-NonOSE_AE
related I-NonOSE_AE
injuries I-NonOSE_AE
. O

For O
patients O
, O
particularly O
the O
elderly O
, O
with O
diseases O
, O
conditions O
, O
or O
medications O
that O
could O
exacerbate O
these O
effects O
, O
assess O
the O
risk O
of O
falls B-NonOSE_AE
when O
initiating O
antipsychotic O
treatment O
and O
recurrently O
for O
patients O
on O
long-term O
antipsychotic O
therapy O
. O

5.9 O
Leukopenia O
, O
Neutropenia O
, O
and O
Agranulocytosis O
Class O
Effect O
: O
In O
clinical O
trial O
and/or O
postmarketing O
experience O
, O
events O
of O
leukopenia B-OSE_Labeled_AE
/ O
neutropenia B-OSE_Labeled_AE
have O
been O
reported O
temporally O
related O
to O
antipsychotic O
agents O
, O
including O
RISPERDAL O
( O
r O
) O
. O

Agranulocytosis B-OSE_Labeled_AE
has O
also O
been O
reported O
. O

Possible O
risk O
factors O
for O
leukopenia B-NonOSE_AE
/ O
neutropenia B-NonOSE_AE
include O
pre-existing O
low B-Not_AE_Candidate
white I-Not_AE_Candidate
blood I-Not_AE_Candidate
cell I-Not_AE_Candidate
count I-Not_AE_Candidate
( I-Not_AE_Candidate
WBC I-Not_AE_Candidate
) O
and O
history O
of O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia/ O
neutropenia I-Not_AE_Candidate
. O

Patients O
with O
a O
history O
of O
a O
clinically O
significant O
low B-Not_AE_Candidate
WBC I-Not_AE_Candidate
or O
a O
drug B-Not_AE_Candidate
- I-Not_AE_Candidate
induced I-Not_AE_Candidate
leukopenia I-Not_AE_Candidate
/neutropenia O
should O
have O
their O
complete O
blood O
count O
( O
CBC O
) O
monitored O
frequently O
during O
the O
first O
few O
months O
of O
therapy O
and O
discontinuation O
of O
RISPERDAL O
( O
r O
) O
should O
be O
considered O
at O
the O
first O
sign O
of O
a O
clinically O
significant O
decline B-NonOSE_AE
in I-NonOSE_AE
WBC I-NonOSE_AE
in O
the O
absence O
of O
other O
causative O
factors O
. O

Patients O
with O
clinically O
significant O
neutropenia B-NonOSE_AE
should O
be O
carefully O
monitored O
for O
fever B-NonOSE_AE
or O
other O
symptoms O
or O
signs O
of O
infection B-NonOSE_AE
and O
treated O
promptly O
if O
such O
symptoms O
or O
signs O
occur O
. O

Patients O
with O
severe O
neutropenia B-NonOSE_AE
( O
absolute B-NonOSE_AE
neutrophil I-NonOSE_AE
count I-NonOSE_AE
< I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
0 I-NonOSE_AE
/ I-NonOSE_AE
mm I-NonOSE_AE
3 I-NonOSE_AE
) O
should O
discontinue O
RISPERDAL O
( O
r O
) O
and O
have O
their O
WBC O
followed O
until O
recovery O
. O

5.10 O
Potential O
for O
Cognitive B-OSE_Labeled_AE
and O
Motor O
Impairment I-OSE_Labeled_AE
Somnolence B-OSE_Labeled_AE
was O
a O
commonly O
reported O
adverse O
reaction O
associated O
with O
RISPERDAL O
( O
r O
) O
treatment O
, O
especially O
when O
ascertained O
by O
direct O
questioning O
of O
patients O
. O

This O
adverse O
reaction O
is O
dose-related O
, O
and O
in O
a O
study O
utilizing O
a O
checklist O
to O
detect O
adverse O
events O
, O
41 O
% O
of O
the O
high-dose O
patients O
( O
RISPERDAL O
( O
r O
) O
16 O
mg/day O
) O
reported O
somnolence B-OSE_Labeled_AE
compared O
to O
16 O
% O
of O
placebo O
patients O
. O

Direct O
questioning O
is O
more O
sensitive O
for O
detecting O
adverse O
events O
than O
spontaneous O
reporting O
, O
by O
which O
8 O
% O
of O
RISPERDAL O
( O
r O
) O
16 O
mg/day O
patients O
and O
1 O
% O
of O
placebo O
patients O
reported O
somnolence B-OSE_Labeled_AE
as O
an O
adverse O
reaction O
. O

Since O
RISPERDAL O
( O
r O
) O
has O
the O
potential O
to O
impair B-OSE_Labeled_AE
judgment I-OSE_Labeled_AE
, O
thinking O
, O
or O
motor O
skills O
, O
patients O
should O
be O
cautioned O
about O
operating O
hazardous O
machinery O
, O
including O
automobiles O
, O
until O
they O
are O
reasonably O
certain O
that O
RISPERDAL O
( O
r O
) O
therapy O
does O
not O
affect O
them O
adversely O
. O

5.11 O
Seizures O
During O
premarketing O
testing O
in O
adult O
patients O
with O
schizophrenia B-Not_AE_Candidate
, O
seizures B-OSE_Labeled_AE
occurred O
in O
0.3 O
% O
( O
9/2607 O
) O
of O
RISPERDAL O
( O
r O
) O
-treated O
patients O
, O
two O
in O
association O
with O
hyponatremia B-NonOSE_AE
. O

RISPERDAL O
( O
r O
) O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
seizures B-Not_AE_Candidate
. O

5.12 O
Dysphagia B-OSE_Labeled_AE
Esophageal B-OSE_Labeled_AE
dysmotility I-OSE_Labeled_AE
and O
aspiration B-OSE_Labeled_AE
have O
been O
associated O
with O
antipsychotic O
drug O
use O
. O

Aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
is O
a O
common O
cause O
of O
morbidity O
and O
mortality O
in O
patients O
with O
advanced O
Alzheimer B-Not_AE_Candidate
' I-Not_AE_Candidate
s I-Not_AE_Candidate
dementia I-Not_AE_Candidate
. O

RISPERDAL O
( O
r O
) O
and O
other O
antipsychotic O
drugs O
should O
be O
used O
cautiously O
in O
patients O
at O
risk O
for O
aspiration B-NonOSE_AE
pneumonia I-NonOSE_AE
. O

[ O
see O
Boxed O
Warning O
and O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
5.13 O
Priapism O
Priapism B-OSE_Labeled_AE
has O
been O
reported O
during O
postmarketing O
surveillance O
. O

Severe O
priapism B-NonOSE_AE
may O
require O
surgical O
intervention O
. O

5.14 O
Body O
Temperature O
Regulation O
Disruption B-OSE_Labeled_AE
of I-OSE_Labeled_AE
body I-OSE_Labeled_AE
temperature I-OSE_Labeled_AE
regulation I-OSE_Labeled_AE
has O
been O
attributed O
to O
antipsychotic O
agents O
. O

Both O
hyperthermia B-OSE_Labeled_AE
and O
hypothermia B-OSE_Labeled_AE
have O
been O
reported O
in O
association O
with O
oral O
RISPERDAL O
( O
r O
) O
use O
. O

Caution O
is O
advised O
when O
prescribing O
for O
patients O
who O
will O
be O
exposed O
to O
temperature O
extremes O
. O

5.15 O
Patients O
with O
Phenylketonuria O
Inform O
patients O
that O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablets O
contain O
phenylalanine O
. O

Phenylalanine O
is O
a O
component O
of O
aspartame O
. O

Each O
4 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.84 O
mg O
phenylalanine O
; O
each O
3 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.63 O
mg O
phenylalanine O
; O
each O
2 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.42 O
mg O
phenylalanine O
; O
each O
1 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.28 O
mg O
phenylalanine O
; O
and O
each O
0.5 O
mg O
RISPERDAL O
( O
r O
) O
M-TAB O
( O
r O
) O
Orally O
Disintegrating O
Tablet O
contains O
0.14 O
mg O
phenylalanine O
. O

